Cancer of unknown primary (CUP) accounts for roughly 3 to 5 percent of all cancer diagnoses, making it one of the ten most common cancer types worldwide. In practical terms, tens of thousands of people each year receive this diagnosis, which means doctors have found cancer that has spread but cannot pinpoint where it originally started, even after extensive testing.
What the Numbers Look Like
CUP is not rare. It ranks among the more frequent cancer diagnoses, though many people have never heard of it. The diagnosis skews older: the median age at diagnosis is 73 for men and 77 for women. Women make up a slightly larger share of cases, accounting for about 54 percent of diagnoses in population-level studies. Nearly 40 percent of patients are over 80 years old, and a significant number, roughly 57 percent, are first diagnosed after an emergency hospital admission rather than through routine screening or outpatient visits.
People from more economically deprived backgrounds appear to be overrepresented. In one large population study, more than a third of CUP patients came from the most deprived socioeconomic group, suggesting that limited access to earlier medical care may play a role in how and when CUP gets caught.
Why the Primary Site Stays Hidden
With most cancers, doctors find the original tumor and then check whether it has spread. CUP works in reverse. The cancer is discovered in one or more places it has traveled to, but the original source either remains too small to detect on imaging, has been destroyed by the body’s immune system, or simply doesn’t produce a visible mass. In some cases, the primary tumor may have regressed entirely while its metastases continued to grow.
To officially classify a case as CUP, doctors need a biopsy-confirmed cancer with no identifiable primary site after pathological evaluation and imaging studies. That workup typically includes immunohistochemistry (staining tissue samples to look for proteins that hint at the cancer’s origin), gene expression profiling, blood markers like PSA or CA-125, and imaging with CT, MRI, or PET scans depending on where the cancer appears. Even with all of these tools, the origin remains genuinely unknown in a substantial number of cases.
Where CUP Typically Shows Up
Because CUP is by definition cancer that has already spread, it tends to appear in the organs that most commonly receive metastases. The most frequent locations at the time of diagnosis are:
- Lymph nodes: 40 to 45 percent of cases
- Liver: 30 to 40 percent
- Lungs: 30 to 40 percent
- Bones: 25 to 35 percent
- Pleura (lining around the lungs): 5 to 15 percent
- Peritoneum (abdominal lining): 5 to 10 percent
- Brain: 5 to 10 percent
Many patients have cancer in more than one of these sites at diagnosis, which is part of what makes identifying the origin so difficult. The pattern of spread sometimes provides indirect clues. For example, cancer found in armpit lymph nodes in a woman often prompts investigation for a hidden breast primary, while cancer in upper neck lymph nodes raises suspicion for a head or neck origin.
Favorable Versus Unfavorable Subtypes
Not all CUP carries the same outlook. Oncologists divide cases into two broad categories based on how the cancer presents and responds to treatment. About 20 to 30 percent of CUP patients fall into what’s called a “favorable” subset, meaning their specific pattern of disease responds relatively well to targeted therapy. The remaining 70 to 80 percent fall into an “unfavorable” group with fewer effective treatment options.
The favorable subtypes include several specific presentations: women with cancer in the abdominal lining that resembles ovarian cancer, women with cancer in armpit lymph nodes that resembles breast cancer, young men with tumors in the chest or midline that may behave like germ cell tumors, squamous cell cancer isolated to neck lymph nodes, and cancer with features matching colon cancer or neuroendocrine tumors. In each of these cases, doctors treat the cancer as though it is the type it most closely resembles, and outcomes can be significantly better.
The distinction matters because patients in the favorable group often respond to the same chemotherapy or treatment approaches used for the cancer their disease mimics. Someone whose CUP looks and behaves like ovarian cancer, for instance, may receive ovarian cancer treatment and do nearly as well as someone with a confirmed ovarian cancer diagnosis.
Why CUP Is Hard to Treat
For the majority of patients in the unfavorable group, treatment is more challenging. Most cancer therapies are designed around a known primary site. Knowing that a cancer started in the lung, for example, guides the choice of drugs that work best against lung cancer biology. Without that anchor, oncologists often rely on broad-spectrum chemotherapy combinations that work across multiple cancer types but may not be optimally matched to the specific tumor.
Overall survival for CUP remains lower than for most cancers with an identified primary. Median survival across all CUP patients is generally reported in the range of 6 to 16 months, though this varies widely depending on the subtype and extent of spread. Patients in the favorable subsets can live considerably longer, sometimes years, while those with widespread unfavorable disease often have a more compressed timeline.
How Molecular Testing Is Changing the Landscape
Advances in genetic and molecular testing are gradually shrinking the proportion of cancers that remain truly “unknown.” Gene expression profiling and next-generation sequencing can now analyze the DNA and RNA of a tumor sample to predict its tissue of origin with increasing accuracy. These tools compare the genetic fingerprint of the unknown cancer against databases of known cancer types, and in many cases can suggest a likely primary site that traditional pathology could not identify.
This matters because when molecular profiling does identify a probable origin, it opens the door to site-specific treatments. A growing body of evidence supports treating CUP patients based on their molecular profile rather than with generic chemotherapy, though this approach is still being refined. Not every cancer center routinely offers comprehensive molecular testing for CUP, but it is becoming more widely available and is increasingly recommended in clinical guidelines.
Even with these advances, a meaningful percentage of CUP cases remain genuinely unclassifiable. The biology of some tumors has diverged so far from its tissue of origin that even sophisticated molecular tools cannot confidently assign it to a primary site. For these patients, treatment decisions continue to rely on the location and behavior of the metastases themselves rather than on a presumed origin.